risks of glp 1 agonists Managing Side Effects GLP-1 Receptor – Transformation Weight Control Mapping the effectiveness and risks

Description

ABSTRACT Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated considerable efficacy in the treatment of diabetes and obesity, it is essential to recognize that their use is associated with certain intrinsic risks that must not be disregarded

has been a member of advisory boards or has consulted with Boehringer Ingelheim, Eli Lilly & Co., Medtronic, Merck, Sharp & Dohme, NovoNordisk, Pfizer, Regor, Sun Pharma and Structure Therapeutics (ShouTi, Gasherbrum)

This process involves neural circuits modulated by neuropeptides, such as corticotropin-releasing factor.150 Dopamine plays a central role in mediating the immediate reinforcing effects of drugs, and dysregulation of the dopaminergic system has been proposed as a predisposing factor for chronic substance use and the maintenance of addiction.151 Dopaminergic neurons originating in the VTA project to the NAcc, amygdala, hippocampus, and prefrontal cortex, while those from the substantia nigra project to the dorsal striatum.152 The activation or disinhibition of VTA dopaminergic neurons is critical for the potentiation of alcohol, nicotine, and opioids.152 Cocaine exerts its effects by inhibits dopamine reuptake by blocking dopamine transporters, thereby increasing or prolonging synaptic dopamine concentrations.152 Other central nervous system stimulants elevate synaptic dopamine via mechanisms such as dopamine reuptake inhibition, reversal of dopamine transporter function, and promotion of dopamine release.153 However, the mechanisms by which GLP-1 receptor stimulation modulates dopaminergic function remain unclear

doi: 10.1002/jcb.24425 72 WangYGYangTL

On the other hand, in the retrospective cohort study using TriNetX Analytics Network electronic health records, semaglutide significantly lowered the risk of both new (HR, 0.27